Boccia, Ralph V <br/><br/>
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.  [electronic resource] 

 -  Clinical colorectal cancer  Apr 2010 
 - 102-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1938-0674 
<br/><br/><label>Standard No.: </label>10.3816/CCC.2010.n.014  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Biomarkers, Tumor<br/>Cetuximab<br/>Colorectal Neoplasms--drug therapy<br/>Confidence Intervals<br/>Disease Progression<br/>Drug Therapy, Combination<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Kaplan-Meier Estimate<br/>Leucovorin--administration & dosage<br/>Male<br/>Middle Aged<br/>Organoplatinum Compounds--administration & dosage<br/>Proto-Oncogene Proteins<br/>Proto-Oncogene Proteins p21(ras)<br/>Treatment Outcome<br/>United States<br/>ras Proteins